Novartis Ag (NVS) Retained Earnings (2009 - 2025)
Novartis Ag's (NVS) quarterly Retained Earnings came in at $45.4 billion in Q4 2025, up 4.87% year-on-year from $43.3 billion in Q4 2024, and up 10.09% quarter-over-quarter from $41.3 billion in Q2 2025.
Novartis Ag (NVS) Retained Earnings (2009 - 2025) Analysis & Trends
Novartis Ag has disclosed Retained Earnings across 11 years of filings, most recently posting $45.4 billion for Q4 2025.
- Retained Earnings for Q4 2025 came in at $45.4 billion, up 4.87% year-over-year; the trailing twelve-month figure through Dec 2025 was $45.4 billion (up 4.87% YoY), and the FY2025 annual result was $45.4 billion, up 4.87% from the prior year.
- Retained Earnings came in at $45.4 billion for Q4 2025 at Novartis Ag, up from $41.3 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $66.8 billion in Q4 2021 to a low of $41.0 billion in Q2 2024.
- The 5-year median for Retained Earnings is $48.5 billion (2023), against an average of $50.9 billion.
- Across the five-year window, Retained Earnings climbed 19.85% in 2021 and fell 21.63% in 2023, its largest moves.
- Novartis Ag's Retained Earnings stood at $66.8 billion in 2021, then dropped by 12.36% to $58.5 billion in 2022, then dropped by 21.63% to $45.9 billion in 2023, then dropped by 5.62% to $43.3 billion in 2024, then grew by 4.87% to $45.4 billion in 2025.
- The last three Retained Earnings figures came in at $45.4 billion (Q4 2025), $41.3 billion (Q2 2025), and $43.3 billion (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 1.90 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 29.51 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | -14.83 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -17.87 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 66.72 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -190.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 78.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -7.20 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -1.37 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 45.41 Bn |
| Jun 30, 2025 | 41.25 Bn |
| Dec 31, 2024 | 43.31 Bn |
| Jun 30, 2024 | 40.97 Bn |
| Dec 31, 2023 | 45.88 Bn |
| Jun 30, 2023 | 51.06 Bn |
| Dec 31, 2022 | 58.54 Bn |
| Jun 30, 2022 | 62.10 Bn |
| Dec 31, 2021 | 66.80 Bn |
| Jun 30, 2021 | 53.19 Bn |
| Dec 31, 2020 | 55.74 Bn |
| Jun 30, 2020 | 52.94 Bn |
| Dec 31, 2019 | 54.62 Bn |
| Jun 30, 2019 | 50.56 Bn |
| Dec 31, 2018 | 77.74 Bn |
| Jun 30, 2018 | 75.93 Bn |
| Dec 31, 2017 | 73.30 Bn |
| Dec 31, 2016 | 73.94 Bn |
| Dec 31, 2009 | 56.56 Bn |